Lumos Diagnostics (ASX:LDX) has signed an agreement with Regional Health Care Group (RHCG), a Henry Schein company in Australia and New Zealand, for the FebriDx point-of-care test.
The agreement further expands FebriDx's distribution through Henry Schein’s medical business to include Australia and New Zealand.
RHCG is part of Henry Schein), the world’s largest healthcare solutions provider to office-based dental and medical practitioners.
“At Henry Schein, our goal is to help health care professionals enhance efficiencies through practice care so they can focus on delivering quality patient care. We are therefore delighted to expand our distribution of FebriDx beyond Portugal, Spain, the Netherlands, the United Kingdom, and the United States to now include Australia and New Zealand,” said Mike Covey, the managing director of Henry Schein Australia.
FebriDx is a rapid point-of-care test to differentiate a viral from a bacterial acute respiratory infection. FebriDx generates results after 10 minutes from fingerstick blood and can be used to help rapidly and accurately manage infectious patients.
“It is great to see the increased interest in our FebriDx test from one of the world’s largest distributors of healthcare and medical products,” said Doug Ward, CEO of Lumos Diagnostics. “Henry Schein has been a terrific and supportive partner for Lumos across Europe. With our recent U.S. launch and the growing commercial interest in FebriDx, we are now preparing production of FebriDx to meet the anticipated growing demand for the product, to support our customers. It is very exciting to have Henry Schein as part of this strategy with their expanded distribution coverage for FebriDx in the Australian and New Zealand markets.”
